Exelixis Inc (EXEL) Stock Price, Quote & News

Company Profile

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosin...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 837 7000

Fax: 650 837 8300

Website: www.exelixis.com

Address:

1851 Harbor Bay Parkway, Alameda, United States

Pr311oma Apr. 23 at 2:45 AM

$EXEL we had a great reason to be up!!! litespark-012 was a major bust!!!!! Merck MRK, along with its partner Eisai, announced that the phase III LITESPARK-012 study, which evaluated Keytruda-based triplet regimens for the first-line treatment of patients with advanced clear cell renal cell carcinoma (RCC), failed to meet its primary endpoints. The LITESPARK-012 study evaluated either the triplet therapy of Keytruda plus Lenvima plus Welireg or MK-1308A (a coformulation of Keytruda and quavonlimab – MRK’s investigational anti-CTLA-4 antibody) plus Lenvima versus Keytruda plus Lenvima for the first-line treatment of patients with advanced clear cell RCC.

1 · Reply

OtherOtttawaGuy Apr. 22 at 7:33 PM

$EXEL Back to our Dec high today, June high by Fri? Heading into uncharted territory once we cross the 50 Mark. It will be an all time high... Regards, OOG

0 · Reply

OtherOtttawaGuy Apr. 22 at 3:02 PM

$EXEL 46.50 next hurdle for past 12 months

1 · Reply

OtherOtttawaGuy Apr. 22 at 2:42 PM

$EXEL Are we now running for the county or state line with the hounds chasing...

0 · Reply

NorthStarStats Apr. 22 at 2:19 AM

Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. Low scores again today. Approach any momentum trades with caution. Go slow and go low. $DGX Score 100, $IBM Score 95, $TRV Score 90, $EXEL Score 73, $FFIV Score 70

0 · Reply

OtherOtttawaGuy Apr. 21 at 8:12 PM

$EXEL Almost made it to the $46.00 tree line. Will see if the guards are watching...

0 · Reply

OtherOtttawaGuy Apr. 21 at 2:58 PM

$EXEL We need to complete the $45.50 jailbreak ...

0 · Reply

OtherOtttawaGuy Apr. 21 at 2:36 PM

$EXEL Seeing some love these past days on $CADL as well... Regards, OOG

2 · Reply

OtherOtttawaGuy Apr. 21 at 1:34 PM

$EXEL Recovery?

0 · Reply

Tangle22 Apr. 20 at 7:22 PM

$EXEL low volume or something else?

0 · Reply

Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026

Mar 11, 2026, 12:00 PM EDT - 6 weeks ago

Exelixis Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 11, 2026, 9:35 AM EDT - 6 weeks ago

Exelixis Transcript: The Citizens Life Sciences Conference 2026

Mar 10, 2026, 10:40 AM EDT - 6 weeks ago

Exelixis Transcript: Leerink Global Healthcare Conference 2026

Mar 3, 2026, 1:10 PM EST - 7 weeks ago

Exelixis Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 4:05 PM EST - 2 months ago

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March

Feb 10, 2026, 5:00 PM EST - 2 months ago

Exelixis Earnings Call Transcript: Q4 2025

Feb 10, 2026, 4:05 PM EST - 2 months ago

Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update

Feb 2, 2026, 8:00 AM EST - 2 months ago

Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer

Jan 27, 2026, 4:05 PM EST - 3 months ago

Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026

Jan 12, 2026, 8:15 PM EST - 3 months ago

Exelixis Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 11, 2026, 4:00 PM EST - 3 months ago

Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026

Jan 7, 2026, 8:00 AM EST - 3 months ago

Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer

NTRA

Jan 6, 2026, 4:05 PM EST - 3 months ago

Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026

Dec 31, 2025, 12:46 PM EST - 4 months ago

See How Rare Bullish Inflows Lift Outliers Like Exelixis

Dec 10, 2025, 1:00 PM EST - 4 months ago

Exelixis Transcript: R&D Day 2025

Dec 3, 2025, 4:05 PM EST - 5 months ago

Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025

Nov 10, 2025, 10:30 AM EST - 5 months ago

Exelixis Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 6, 2025, 4:05 PM EST - 6 months ago

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

Nov 4, 2025, 5:00 PM EST - 6 months ago

Exelixis Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:05 PM EST - 6 months ago

Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 21, 2025, 4:05 PM EDT - 6 months ago

Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Oct 20, 2025, 10:48 AM EDT - 6 months ago

Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results

Oct 20, 2025, 2:30 AM EDT - 6 months ago

Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet

Oct 18, 2025, 3:00 AM EDT - 6 months ago

Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025

Sep 24, 2025, 8:50 AM EDT - 7 months ago

Exelixis Transcript: Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum

Sep 10, 2025, 8:00 AM EDT - 8 months ago

Exelixis Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 8:30 AM EDT - 8 months ago

Exelixis Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 4, 2025, 10:06 AM EDT - 8 months ago

EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm

Sep 3, 2025, 3:15 PM EDT - 8 months ago

Exelixis Transcript: Citi's Biopharma Back to School Conference

Sep 3, 2025, 12:45 PM EDT - 8 months ago

Exelixis Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Aug 29, 2025, 5:47 PM EDT - 8 months ago

Exelixis Announces Appointment of Dana T. Aftab, Ph.D.

Aug 27, 2025, 4:05 PM EDT - 8 months ago

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September

Jul 29, 2025, 12:32 PM EDT - 9 months ago

Analyst Surprised By Exelixis Q2 Revenue Miss, Delays STELLAR-304 Readout, Halts STELLAR-305 Phase 3 Plans

Jul 28, 2025, 5:00 PM EDT - 9 months ago

Exelixis Earnings Call Transcript: Q2 2025

Jul 28, 2025, 4:05 PM EDT - 9 months ago

Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 24, 2025, 5:04 PM EDT - 9 months ago

Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Jul 14, 2025, 4:05 PM EDT - 10 months ago

Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025

Jun 23, 2025, 10:37 AM EDT - 10 months ago

Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars

Jun 22, 2025, 5:00 PM EDT - 10 months ago

Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer

Jun 20, 2025, 6:54 AM EDT - 11 months ago

Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Jun 4, 2025, 7:35 AM EDT - 11 months ago

Exelixis Transcript: Jefferies Global Healthcare Conference 2025

Jun 3, 2025, 11:00 AM EDT - 11 months ago

Exelixis Transcript: 45th Annual William Blair Growth Stock Conference

May 27, 2025, 2:30 PM EDT - 11 months ago

Exelixis Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

May 23, 2025, 6:25 AM EDT - 1 year ago

Product Performance, Big Money Lift Exelixis

May 22, 2025, 5:17 PM EDT - 1 year ago

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025

May 22, 2025, 4:05 PM EDT - 1 year ago

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June

May 20, 2025, 10:30 AM EDT - 1 year ago

Exelixis Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 14, 2025, 1:40 PM EDT - 1 year ago

Exelixis Transcript: BofA Securities 2025 Healthcare Conference

May 14, 2025, 10:44 AM EDT - 1 year ago

Exelixis Crushes Q1 Earnings Estimates With Strong Cabometyx Sales, Raises 2025 Revenue Guidance

May 13, 2025, 6:06 PM EDT - 1 year ago

Invenra Highlights Exelixis' Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors

May 13, 2025, 5:00 PM EDT - 1 year ago

Exelixis Earnings Call Transcript: Q1 2025

May 13, 2025, 4:07 PM EDT - 1 year ago

Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 7, 2025, 4:05 PM EDT - 1 year ago

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May

Apr 29, 2025, 4:05 PM EDT - 1 year ago

Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025

Apr 29, 2025, 2:02 AM EDT - 1 year ago

EXEL Industries: Second quarter 2024–2025 sales down 3.8%

Mar 26, 2025, 9:15 AM EDT - 1 year ago

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Mar 25, 2025, 5:15 PM EDT - 1 year ago

Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025

Mar 19, 2025, 7:09 AM EDT - 1 year ago

Exelixis Growth Continues with Big Money Boosts

Mar 12, 2025, 10:40 AM EDT - 1 year ago

Exelixis Transcript: Leerink Global Healthcare Conference 2025

Mar 11, 2025, 1:30 PM EDT - 1 year ago

Exelixis Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 4, 2025, 9:50 AM EST - 1 year ago

Exelixis Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 25, 2025, 4:05 PM EST - 1 year ago

Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March

Feb 21, 2025, 1:30 PM EST - 1 year ago

Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?

Feb 20, 2025, 5:05 PM EST - 1 year ago

Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program

Feb 19, 2025, 2:00 PM EST - 1 year ago

Exelixis Transcript: Citi's 2025 Virtual Oncology Leadership Summit

Feb 15, 2025, 11:10 AM EST - 1 year ago

Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025

Feb 13, 2025, 4:05 PM EST - 1 year ago

Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit

Feb 11, 2025, 5:00 PM EST - 1 year ago

Exelixis Earnings Call Transcript: Q4 2024

Feb 11, 2025, 4:05 PM EST - 1 year ago

Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update

Jan 28, 2025, 4:05 PM EST - 1 year ago

Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

Jan 25, 2025, 10:00 AM EST - 1 year ago

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025

Jan 24, 2025, 2:30 PM EST - 1 year ago

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025

Jan 13, 2025, 8:15 PM EST - 1 year ago

Exelixis Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Dec 4, 2024, 1:45 PM EST - 1 year ago

Exelixis Transcript: Citi's 2024 Global Healthcare Conference

Dec 3, 2024, 8:30 AM EST - 1 year ago

Exelixis Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 5:30 AM EST - 1 year ago

Exelixis Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 10:20 AM EST - 1 year ago

Exelixis Transcript: Stifel 2024 Healthcare Conference

Nov 12, 2024, 9:00 AM EST - 1 year ago

Exelixis Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Oct 29, 2024, 5:00 PM EDT - 1 year ago

Exelixis Earnings Call Transcript: Q3 2024

Sep 18, 2024, 5:50 AM EDT - 1 year ago

Exelixis Transcript: Bank of America Global Healthcare Conference

Sep 6, 2024, 10:15 AM EDT - 1 year ago

Exelixis Transcript: 2024 Wells Fargo Healthcare Conference

Sep 4, 2024, 9:15 AM EDT - 1 year ago

Exelixis Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 6, 2024, 5:00 PM EDT - 1 year ago

Exelixis Earnings Call Transcript: Q2 2024

Jun 4, 2024, 4:20 PM EDT - 2 years ago

Exelixis Transcript: The 44th Annual William Blair Growth Stock Conference

May 14, 2024, 2:35 PM EDT - 2 years ago

Exelixis Transcript: 2024 RBC Capital Markets Global Healthcare Conference

May 14, 2024, 2:20 PM EDT - 2 years ago

Exelixis Transcript: BofA Securities 2024 Health Care Conference

May 14, 2024, 9:30 AM EDT - 2 years ago

Exelixis Transcript: The Citizens JMP Life Sciences Conference

Apr 30, 2024, 5:00 PM EDT - 2 years ago

Exelixis Earnings Call Transcript: Q1 2024

Mar 13, 2024, 10:45 AM EDT - 2 years ago

Exelixis Transcript: Barclays 26th Annual Global Healthcare Conference 2024

Mar 12, 2024, 9:20 AM EDT - 2 years ago

Exelixis Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 5, 2024, 10:30 AM EST - 2 years ago

Exelixis Transcript: TD Cowen 44th Annual Health Care Conference 2024

Feb 13, 2024, 12:40 PM EST - 2 years ago

Exelixis Transcript: Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 8, 2024, 9:00 AM EST - 2 years ago

Exelixis Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Feb 6, 2024, 5:00 PM EST - 2 years ago

Exelixis Earnings Call Transcript: Q4 2023

Jan 8, 2024, 7:30 PM EST - 2 years ago

Exelixis Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Dec 12, 2023, 9:00 AM EST - 2 years ago

Exelixis Transcript: R&D Day 2023

Nov 28, 2023, 11:00 AM EST - 2 years ago

Exelixis Transcript: Piper Sandler 35th Annual Healthcare Conference

Nov 1, 2023, 5:00 PM EDT - 2 years ago

Exelixis Earnings Call Transcript: Q3 2023

Sep 12, 2023, 1:35 PM EDT - 2 years ago

Exelixis Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Sep 8, 2023, 11:00 AM EDT - 2 years ago

Exelixis Transcript: Wells Fargo Securities Healthcare Conference 2023

Aug 1, 2023, 5:00 PM EDT - 2 years ago

Exelixis Earnings Call Transcript: Q2 2023

Jun 13, 2023, 7:00 PM EDT - 3 years ago

Exelixis Transcript: Goldman Sachs 44th Annual Global Healthcare Conference

May 9, 2023, 5:00 PM EDT - 3 years ago

Exelixis Earnings Call Transcript: Q1 2023

Mar 16, 2023, 10:00 AM EDT - 3 years ago

Exelixis Transcript: Guggenheim Healthy Altitudes Summit

Mar 14, 2023, 1:20 PM EDT - 3 years ago

Exelixis Transcript: Barclays Global Healthcare Conference

Mar 7, 2023, 1:30 PM EST - 3 years ago

Exelixis Transcript: Cowen Health Care Conference

Feb 15, 2023, 2:20 PM EST - 3 years ago

Exelixis Transcript: SVB Securities Global Biopharma Conference

Feb 9, 2023, 11:20 AM EST - 3 years ago

Exelixis Transcript: Guggenheim Healthcare Talks Oncology Day

Feb 7, 2023, 5:00 PM EST - 3 years ago

Exelixis Earnings Call Transcript: Q4 2022

Jan 9, 2023, 8:15 PM EST - 3 years ago

Exelixis Transcript: JPMorgan Healthcare Conference

Nov 1, 2022, 5:00 PM EDT - 3 years ago

Exelixis Earnings Call Transcript: Q3 2022

Aug 9, 2022, 5:00 PM EDT - 4 years ago

Exelixis Earnings Call Transcript: Q2 2022

May 10, 2022, 9:07 AM EDT - 4 years ago

Exelixis Earnings Call Transcript: Q1 2022

Feb 16, 2022, 7:37 PM EST - 4 years ago

Exelixis Earnings Call Transcript: Q4 2021

Nov 2, 2021, 5:00 PM EDT - 4 years ago

Exelixis Earnings Call Transcript: Q3 2021

Aug 5, 2021, 5:00 PM EDT - 5 years ago

Exelixis Earnings Call Transcript: Q2 2021

May 26, 2021, 12:00 PM EDT - 5 years ago

Exelixis Transcript: AGM 2021

May 6, 2021, 5:00 PM EDT - 5 years ago

Exelixis Earnings Call Transcript: Q1 2021

Feb 10, 2021, 5:00 PM EST - 5 years ago

Exelixis Earnings Call Transcript: Q4 2020

Nov 5, 2020, 5:00 PM EST - 5 years ago

Exelixis Earnings Call Transcript: Q3 2020

Aug 6, 2020, 5:30 PM EDT - 6 years ago

Exelixis Earnings Call Transcript: Q2 2020

May 5, 2020, 5:00 PM EDT - 6 years ago

Exelixis Earnings Call Transcript: Q1 2020

Pr311oma Apr. 23 at 2:45 AM

1 · Reply

OtherOtttawaGuy Apr. 22 at 7:33 PM

$EXEL Back to our Dec high today, June high by Fri? Heading into uncharted territory once we cross the 50 Mark. It will be an all time high... Regards, OOG

0 · Reply

OtherOtttawaGuy Apr. 22 at 3:02 PM

$EXEL 46.50 next hurdle for past 12 months

1 · Reply

OtherOtttawaGuy Apr. 22 at 2:42 PM

$EXEL Are we now running for the county or state line with the hounds chasing...

0 · Reply

NorthStarStats Apr. 22 at 2:19 AM

0 · Reply

OtherOtttawaGuy Apr. 21 at 8:12 PM

$EXEL Almost made it to the $46.00 tree line. Will see if the guards are watching...

0 · Reply

OtherOtttawaGuy Apr. 21 at 2:58 PM

$EXEL We need to complete the $45.50 jailbreak ...

0 · Reply

OtherOtttawaGuy Apr. 21 at 2:36 PM

$EXEL Seeing some love these past days on $CADL as well... Regards, OOG

2 · Reply

OtherOtttawaGuy Apr. 21 at 1:34 PM

$EXEL Recovery?

0 · Reply

Tangle22 Apr. 20 at 7:22 PM

$EXEL low volume or something else?

0 · Reply

robins1 Apr. 18 at 1:38 AM

$EXEL most likely the board of Directors sold more shares at a high price since they give themselves shares as gift and this way they control the price not to go up

0 · Reply

OtherOtttawaGuy Apr. 16 at 2:50 AM

$EXEL Regression extension shows this busting 50 between Aug and Oct of this year. Will wsit and see I guess. OIG

0 · Reply

Tangle22 Apr. 16 at 12:11 AM

$EXEL what causes today’s big drop?

0 · Reply

OtherOtttawaGuy Apr. 14 at 2:33 PM

$EXEL Now can we stay north of $45.50. Maybe a new 52 week high?

0 · Reply

Doozio Apr. 13 at 8:26 PM

If YO AXSMbody n they gave a sign to $EXEL ONTO 🐒🍌🧠⏰♾️

1 · Reply

OtherOtttawaGuy Apr. 10 at 2:40 PM

$EXEL This stock seems to keep bouncing right off the 45.50 mark. Would love to see this run to a new 52 week that starts with a 5...lol Regards, OOG

0 · Reply

Doozio Apr. 10 at 1:13 AM

The list of proper bases as da 🐑 been spot n da 🧠 is ready to $EXEL $AXSM body whut time it is…..

0 · Reply

Doozio Apr. 1 at 7:17 PM

So the 🧠 won’t $EXEL ? Or $NEXT week on the dip or $NXT week on da bahhhhhreakoout? Chop chop huckleberries……

0 · Reply

Doozio Mar. 31 at 2:17 PM

If da 🧠 is gonna $EXEL out da tightness yo bettah $AXSM body.

0 · Reply

Doozio Mar. 31 at 2:05 PM

Roger shall rock his $HALO and da 🧠 shall $EXEL again out of the tightness.

0 · Reply

Nasfact Mar. 30 at 9:34 PM

$SLS still thinking of Exelixis $EXEL in 2015/16 FIRST-Line RCC expansion. SLS009 will show how its done IMO!

1 · Reply

DavyDaveCharts Mar. 29 at 7:02 PM

$EXEL quarterly: imbalance and breaker in the mid-upper 20's.

0 · Reply

Market Cap	11.70B
Revenue (ttm)	2.32B
Net Income (ttm)	782.57M
EPS (ttm)	N/A
PE Ratio	16.81
Forward PE	14.98
Profit Margin	33.73%
Debt to Equity Ratio	0.00

Volume	2,342,900
Avg Vol	2,747,964
Day's Range	N/A - N/A
Shares Out	254.01M
Stochastic %K	36%
Beta	0.42
Analysts	Sell
Price Target	$46.89